COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Rodriguez, Zahidee, Shane, Andi L., Verkerke, Hans, Lough, Christopher, Zimmerman, Matthew G., Suthar, Mehul, Wrammert, Jens, MacDonald, Heather, Wolf, Michael, Clarke, Shanelle, Roback, John D., Arthur, Connie M., Stowell, Sean R., Josephson, Cassandra D.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Exceptional Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509858/
https://ncbi.nlm.nih.gov/pubmed/32915971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002507
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars